Cargando…

Inhibition of Chondrosarcoma Growth by mTOR Inhibitor in an In Vivo Syngeneic Rat Model

BACKGROUND: Chondrosarcomas are the second most frequent primary malignant type of bone tumor. No effective systemic treatment has been identified in advanced or adjuvant phases for chondrosarcoma. The aim of the present study was to determine the antitumor effects of doxorubicin and everolimus, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perez, Jennifer, Decouvelaere, Anne Valérie, Pointecouteau, Thomas, Pissaloux, Daniel, Michot, Jean Philippe, Besse, Anthony, Blay, Jean Yves, Dutour, Aurélie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384598/ https://www.ncbi.nlm.nih.gov/pubmed/22761648 http://dx.doi.org/10.1371/journal.pone.0032458

Ejemplares similares

miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas
por: Gougelet, Angélique, et al.
Publicado: (2011)

The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target
por: Iseulys, Richert, et al.
Publicado: (2019)

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
por: de Jong, Yvonne, et al.
Publicado: (2018)

Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway
por: Addie, Ruben D., et al.
Publicado: (2019)

Radiotherapy in bone sarcoma: the quest for better treatment option
por: Locquet, Marie-Anaïs, et al.
Publicado: (2023)

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
por: Bally, Olivia, et al.
Publicado: (2015)

Prediction of desmoid tumor progression using miRNA expression profiling
por: Dufresne, Armelle, et al.
Publicado: (2015)

Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients
por: Brahmi, Mehdi, et al.
Publicado: (2015)

Aldehyde Dehydrogenase, a Therapeutic Target in Chordoma: Analysis in 3D Cellular Models
por: Locquet, Marie-Anaïs, et al.
Publicado: (2021)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer
por: Cash, Harrison, et al.
Publicado: (2015)

KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome
por: Brahmi, Mehdi, et al.
Publicado: (2015)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition
por: Charette, Nicolas, et al.
Publicado: (2010)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Constitutive GLI1 expression in chondrosarcoma is regulated by major vault protein via mTOR/S6K1 signaling cascade
por: Wang, Wei, et al.
Publicado: (2021)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression
por: Nicolle, Rémy, et al.
Publicado: (2019)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through PI3K, Akt, mTOR, and HIF-α pathway
por: Lee, Hsiang-Ping, et al.
Publicado: (2015)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Selective, high-contrast detection of syngeneic glioblastoma in vivo
por: Banati, Richard B., et al.
Publicado: (2020)

Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?
por: Gatault, Philippe, et al.
Publicado: (2013)

A“Proteoglycan Targeting Strategy” for the Scintigraphic Imaging and Monitoring of the Swarm Rat Chondrosarcoma Orthotopic Model
por: Peyrode, Caroline, et al.
Publicado: (2011)

mTOR inhibitors activate PERK signaling and favor viability of gastrointestinal neuroendocrine cell lines
por: Freis, Patricia, et al.
Publicado: (2017)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Predicted mechanisms of resistance to mTOR inhibitors
por: Kurmasheva, R T, et al.
Publicado: (2006)

mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)

Practical considerations for the use of mTOR inhibitors
por: Diekmann, Fritz, et al.
Publicado: (2015)

Deptor: not only a mTOR inhibitor
por: Catena, Valeria, et al.
Publicado: (2017)

Role of mTOR Inhibitors in Kidney Disease
por: Kajiwara, Moto, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vhhlks137ol9emfdvpfh7g7ggg